Tada,

If Zen 3694 is extending the lifespan  of those with advanced metastatic prostate cancer   past 6 months and longer, what is Zeneth Epigenetic worth to a company like Pfizer who paid 14 Billion for Medivation , , I got think that even at a phase 1 trial if the Zen 3694 is doing waht it is suppose to do, Zenith should theoritically be sold for a 1/4 to a third of what Medivation was sold for being an approved FDA drug..  Maybe a competitor to Pfizer in the same field might want to take a chance on this flyer??  it has been awfully quiet, i hope that has to do with some negotitions for a deal of soem sort,